Hyperglycaemia · Neonates with developing BPD
Inhaled steroids showed no clear difference in hyperglycaemia compared with systemic steroids (low certainty).
1 finding from 1 review
Hypertension · Neonates with developing BPD
Inhaled steroids may leads to lower hypertension compared with systemic steroids (low certainty).
1 finding from 1 review
General conceptual ability (GCA) score at 7 years The test has a standardisation mean of 100 and SD of 15 · Neonates with developing BPD
Inhaled steroids showed no clear difference in general conceptual ability (GCA) score at 7 years The test has a… compared with systemic steroids (moderate certainty).
1 finding from 1 review
Moderate/severe disability at 7 years · Neonates with developing BPD
Inhaled steroids showed no clear difference in moderate/severe disability at 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
Death or moderate/severe disability at 7 years · Neonates with developing BPD
Inhaled steroids showed no clear difference in death or moderate/severe disability at 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
Systolic blood pressure > 95th percentile at 7 years · Neonates with developing BPD
Inhaled steroids showed no clear difference in systolic blood pressure > 95th percentile at 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
BPD or death at 36 weeks' postmenstrual age№ of participants: 0 (0 RCTs) · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in death or BPD at 36 weeks' postmenstrual age among all randomised compared with systemic corticosteroids (moderate certainty).
1 finding from 1 review
Intervention not reported
BPD at 28 days · Preterm neonates with respiratory distress
The intervention showed no clear difference in BPD at 28 days (low certainty).
1 finding from 1 review
Intervention not reported
Ever diagnosed as asthmatic by 7 years of age · Preterm neonates with respiratory distress
The intervention probably leads to lower ever diagnosed as asthmatic by 7 years of age (moderate certainty).
1 finding from 1 review
Death or BPD (28 days) · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in death or BPD at 28 days compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in BPD at 36 weeks' postmenstrual age compared with systemic corticosteroids (moderate certainty).
1 finding from 1 review
BPD at 28 days · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in BPD at 28 days compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Intervention not reported
Duration of mechanical ventilation (days) · Preterm neonates with respiratory distress
1 finding from 1 review
Intervention not reported
Duration of supplemental oxygen (days) · Preterm neonates with respiratory distress
1 finding from 1 review
Intervention not reported
Hyperglycaemia · Preterm neonates with respiratory distress
The intervention probably leads to lower hyperglycaemia (moderate certainty).
1 finding from 1 review
Intervention not reported
Patent ductus arteriosus · Preterm neonates with respiratory distress
The intervention probably leads to higher patent ductus arteriosus (moderate certainty).
1 finding from 1 review
Intervention not reported
BPD at 36 weeks' postmenstrual age · Preterm neonates with respiratory distress
The intervention showed no clear difference in BPD at 36 weeks' postmenstrual age (moderate certainty).
1 finding from 1 review
Intervention not reported
Functional exercise capacity Multiple different outcome measures used SF‐36 PF and AT (at 9 and 26 weeks) (Batterham 2014) SF‐36 PF and 6MWT (at 8 and 26 weeks) (Elliott 2011) ABC, Katz, TUAG (at 3 months) (Jackson 2012) SF‐36 PCS ( · adult survivors of critical illness
1 finding from 1 review
Intervention not reported
Health‐related quality of life Multiple different outcome measures used EQ‐5D and EQ‐5D VAS (9 and 26 weeks) (Batterham 2014) SF‐36 PCS and MCS (8 and 26 weeks) (Elliott 2011) · adult survivors of critical illness
1 finding from 1 review
Intervention not reported
Adherence Participant completion of the intervention as described in the trial method · adult survivors of critical illness
1 finding from 1 review